Glaucoma, Open-Angle
Conditions
Brief summary
To prospectively assess the clinical effect of ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System in pseudophakic eyes on intraocular pressure (IOP) and the use of IOP-lowering medications in patients with open angle glaucoma (OAG).
Interventions
DEVICEOMNI® Surgical System
Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
Sponsors
Sight Sciences, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female subjects, 22 years or older at the time of surgery * History of uncomplicated cataract surgery and posterior chamber IOL implantation without compromise to the lens capsule, zonular dehiscence/rupture or vitreous prolapse, 6 months or more prior to Baseline Visit. * Diagnosed with mild to moderate open angle glaucoma (e.g. primary open angle glaucoma, pigmentary glaucoma, pseudoexfoliative glaucoma) as documented in subjects' medical record substantiated using funduscopic exam or OCT and at least one visual field test with the Humphrey automated perimeter using the SITA Standard 24-2 testing algorithm. * Mean deviation score must be better than or equal to -12.0 dB * The visual field test may be historical (within 6 months prior to Screening Visit). If needed, visual field testing may be repeated between the Screening Visit and the Surgery Visit. * At the Screening visit, IOP of ≤ 36 mmHg while on 1-5 ocular hypotensive medications1 with a stable medication regimen for at least 2 months. * At Baseline visit, unmedicated diurnal i) IOP ≥ 22.5 and ≤ 39mmHg and ii) IOP at least 3 mmHg higher than screening IOP and iii) IOP at 7:30AM ≥ 24 * Scheduled for ab-interno transluminal viscoelastic delivery and trabeculotomy using the OMNI Surgical System. * Shaffer grade of ≥ III in all four quadrants * Able and willing to comply with the protocol, including all follow-up visits. * Understands and signs the informed consent
Exclusion criteria
* Any of the following prior treatments for glaucoma: * Laser trabeculoplasty ≤3 months prior to Baseline visit * iStent or iStent Inject implanted ≤6 months prior to Baseline visit * Endocyclophotocoagulation (ECP) or Micropulse laser ≤ 6 months prior to Baseline visit * Trabeculectomy or other bleb forming procedure including Xen, Express, glaucoma draining device/valve * Prior canaloplasty, goniotomy, or trabeculotomy * Hydrus microstent * Suprachoroidal stent (e.g. Cypass, iStent Supra) * Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma * Concurrent IOP-lowering procedure other than use of the OMNI Surgical System at the time of surgery (e.g. ECP, CPC, etc.) * In the Investigator's judgement, predisposed to significant risk because of washout of ocular hypotensive medications * Concurrent ocular pathology or systemic medical condition which, in the Investigator's judgment, would either place the subject at increased risk of complications, contraindicate surgery, place the subject at risk of significant vision loss during the study period (e.g., wet AMD, corneal edema, Fuch's dystrophy, active intraocular infection or inflammation within 30 days prior to Screening Visit, etc.), or interfere with compliance to elements of the study protocol (e.g., returning to Investigator's office for follow-up visits). * History of penetrating keratoplasty or another corneal transplant * BCVA of logMAR 1.0 (20/200) or worse in the fellow eye not due to cataract * Study of OMNI System in POAG * BCVA of logMAR 0.4 (20/50) or worse in the study eye not due to posterior capsular opacification (uneventful Nd:YAG laser capsulotomy 6 months prior to baseline is permitted only if there is no vitreous present in or in front of the iris plane at the time of baseline). * Participation (≤ 30 days prior to baseline) in an interventional trial which could have a potential effect on the study outcome, as determined by the study investigator * Women of childbearing potential if they are currently pregnant or intend to become pregnant during the study period; are breast-feeding; or are not in agreement to use adequate birth control methods to prevent pregnancy throughout the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Intraocular Pressure (IOP) | 6 months | Change in unmedicated mean diurnal IOP (DIOP) for subjects who reached the 6-month post-operative timepoint by the time of study closure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Number of Medications | 6 months | Change in the number of ocular hypotensive medications between screening and 6 months for subjects who reached the 6-month post-operative timepoint by the time of study closure |
Countries
United States
Participant flow
Recruitment details
The enrollment period for the study lasted 7 months and the study included 11 sites across the USA
Participants by arm
| Arm | Count |
|---|---|
| Pseudophakic Eyes With Open Angle Glaucoma Eligible subjects enrolled in the trial will receive surgery for Open Angle Glaucoma using the OMNI® Surgical System.
OMNI® Surgical System: Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System | 54 |
| Total | 54 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Baseline failure | 16 |
| Overall Study | Screen failure | 8 |
| Overall Study | Sponsor Decision to terminate the study | 54 |
Baseline characteristics
| Characteristic | Pseudophakic Eyes With Open Angle Glaucoma |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 45 Participants |
| Age, Categorical Between 18 and 65 years | 9 Participants |
| Age, Continuous | 73.2 years STANDARD_DEVIATION 7.6 |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 51 Participants |
| Region of Enrollment United States | 54 participants |
| Sex: Female, Male Female | 35 Participants |
| Sex: Female, Male Male | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 78 |
| other Total, other adverse events | 20 / 78 |
| serious Total, serious adverse events | 2 / 78 |
Outcome results
Primary
Change in Intraocular Pressure (IOP)
Change in unmedicated mean diurnal IOP (DIOP) for subjects who reached the 6-month post-operative timepoint by the time of study closure
Time frame: 6 months
Population: Overall mean change in IOP from baseline for subjects who reached the 6-month time point by study closure
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Pseudophakic Eyes With Open Angle Glaucoma | Change in Intraocular Pressure (IOP) | -8.8 mmHg | Standard Deviation 7.3 |
Secondary
Change in Number of Medications
Change in the number of ocular hypotensive medications between screening and 6 months for subjects who reached the 6-month post-operative timepoint by the time of study closure
Time frame: 6 months
Population: Overall mean change in number of ocular hypotensive medications from Screening for enrolled subjects who reached the 6-month post-operative time point at the time of study closure
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Pseudophakic Eyes With Open Angle Glaucoma | Change in Number of Medications | -1.2 number of hypotensive medications | Standard Deviation 1.3 |